New SOLUTIONS
for autoimmune and inflammatory diseases
New SOLUTIONS
for autoimmune and inflammatory diseases
New SOLUTIONS
for autoimmune and inflammatory diseases
Clinical studies
Medsenic, a subsidiary of BioSenic, has signed a conditional letter of intent that could secure funding to cover part of the costs for its clinical trial on chronic graft-versus-host disease
Mont-Saint-Guibert, Belgium, 13 December 2024, 17:30 CET – BIOSENIC (Euronext Brussels and Paris : BIOS) announces the signing of a conditional letter of intent between Medsenic SAS and the Singapo
Arsenic Trioxide
An innovative drug to treat autoimmune diseases at the source of the immune cascade.
Our technology
BioSenic offers a unique treatment value by developing two innovative product lines: an arsenic trioxide-based treatment for autoimmune diseases and cell therapy products.
BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact